1. Usefulness and Safety of Endoscopic Nasobiliary Drainage for Type 1 Autoimmune Pancreatitis.
- Author
-
Ito T, Ikeura T, Nakamaru K, Masuda M, Nakayama S, Shimatani M, Uchida K, Takaoka M, Okazaki K, and Naganuma M
- Abstract
Objectives: Autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4-related disease which is complicated by extra-pancreatic lesions such as IgG4-related sclerosing cholangitis. The appropriate biliary drainage method and period for type 1 AIP remain unclear. Therefore, we aimed to clarify the usefulness and safety of endoscopic nasobiliary drainage (ENBD) for type 1 AIP in patients with jaundice., Methods: This study enrolled 83 patients with type 1 AIP who underwent steroid therapy who underwent evaluation of contrast material outflow to the jejunum using cholangiography. The ENBD was removed when the contrast material outflowed into the duodenum; an endoscopic biliary stenting (EBS) was performed if it did not outflow., Results: Cholangiography and pancreatography were achieved in 83 (100%) and 77 (93%) patients, respectively. Liver function parameters were significantly decreased after ENBD. Bile juice cytology using ENBD revealed no evidence of malignancy. Two (2%) patients developed mild pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic ultrasound-guided fine-needle aspiration biopsy was performed in 56 (67%) patients. ENBD was removed in 75 (90%) patients; EBS was performed in 8 (10%). Multivariate regression analysis showed pancreatic focal enlargement (OR=12.06, 95% CI: 1.28-113.62, P=0.03) as an independent risk factor for EBS., Conclusions: Although ENBD causes discomfort and the risk of self-removal, it differentiates AIP from malignant tumors, evaluates steroid effects using real-time cholangiography, and reduces the number of required ERCP procedures. ENBD could be one of the drainage options for type 1 AIP, depending on patients' background., Competing Interests: Conflict of interest: Takashi Ito, Tsukasa Ikeura, Masataka Masuda, Koh Nakamaru, Masaaki Shimatani, Kazushige Uchida, Makoto Takaoka, Kazuichi Okazaki, Makoto Naganuma have no conflict of interest or financial ties to disclose. Conflicts of Interest: The authors declare that they have no conflict of interest., (Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF